68/100

Moderate evidence

Cite
More
EmailLinkedInX

Blood test using portable light scanner tested on 280 people to sort ovarian tumors

Study title: Rapid serum-based differentiation of ovarian tumors and assessment of post-treatment disease-free status using portable Raman spectroscopy and machine learning

Evidence type
Controlled or validated comparison
Sample
n = 280
Sources
1 sourcePeer-reviewed
Published
1 min read

Study title: Rapid serum-based differentiation of ovarian tumors and assessment of post-treatment disease-free status using portable Raman spectroscopy and machine learning

Rapid, low-cost tools for ovarian tumor discrimination and post-treatment assessment remain limited because conventional serum biomarkers such as CA125 have suboptimal sensitivity and specificity. Serum contains proteins, lipids, carbohydrates, and nucleic acids that generate disease-related spectrochemical fingerprints, which portable Raman spectroscopy can capture with minimal sample preparation.

Read the study abstract

Rapid, low-cost tools for ovarian tumor discrimination and post-treatment assessment remain limited because conventional serum biomarkers such as CA125 have suboptimal sensitivity and specificity. Serum contains proteins, lipids, carbohydrates, and nucleic acids that generate disease-related spectrochemical fingerprints, which portable Raman spectroscopy can capture with minimal sample preparation. We investigated serum Raman profiling for ovarian tumor discrimination and cross-sectional characterization of post…

Rapid serum-based differentiation of ovarian tumors and assessment of post-treatment disease-free status using portable Raman spectroscopy and machine learning
NABL Accredited Clinical Pathology Laboratory in Kharghar Navi Mumbai Diagnostic Services by Goleisureintl. CC BY 4.0 · Wikimedia Commons

The gain

Portable Raman spectroscopy with machine learning offers a rapid, low-cost serum approach to distinguish ovarian tumors and assess post-treatment status, where CA125 is limited.

In brief

We investigated serum Raman profiling for ovarian tumor discrimination and cross-sectional characterization of post-treatment disease-free status. Serum samples from 280 participants (85 benign, 82 malignant, and 113 independent follow-up patients) were analyzed over 400-1800 cm⁻ 1 .

Main points

  1. Rapid, low-cost tools for ovarian tumor discrimination and post-treatment assessment remain limited because conventional serum biomarkers such as CA125 have suboptimal sensitivity and specificity.
  2. Serum contains proteins, lipids, carbohydrates, and nucleic acids that generate disease-related spectrochemical fingerprints, which portable Raman spectroscopy can capture with minimal sample preparation.
  3. We investigated serum Raman profiling for ovarian tumor discrimination and cross-sectional characterization of post-treatment disease-free status.

The full story

Rapid, low-cost tools for ovarian tumor discrimination and post-treatment assessment remain limited because conventional serum biomarkers such as CA125 have suboptimal sensitivity and specificity. Serum contains proteins, lipids, carbohydrates, and nucleic acids that generate disease-related spectrochemical fingerprints, which portable Raman spectroscopy can capture with minimal sample preparation.

Sources

1 on file
  1. Analytical and Bioanalytical Chemistrydoi:10.1007/s00216-026-06823-5
    Peer-reviewed2026-09-23

Talk it over

What readers make of this record

What readers say